Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient


News provided by

Mylan N.V.

Dec 04, 2018, 11:30 ET

Share this article

Share toX

Share this article

Share toX

HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).  

Continue Reading

Out of an abundance of caution, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited. These batches were distributed in the U.S. between March 2017 and November 2018.  The expanded recalled batches are as follows:

NDC

Name and Strength

Size

Lot No

Expiry

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3064084

1/2019

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3069629

5/2019

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3073148

8/2019

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3073149

8/2019

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3076093

10/2019

0378-1721-93

Amlodipine and Valsartan Tablets, USP  5/160 mg

Bottles of 30

3077772

11/2019

0378-1722-93

Amlodipine and Valsartan Tablets, USP 10/160 mg

Bottles of 30

3064085

1/2019

0378-1722-93

Amlodipine and Valsartan Tablets, USP 10/160 mg

Bottles of 30

3066063

3/2019

0378-1722-93

Amlodipine and Valsartan Tablets, USP 10/160 mg

Bottles of 30

3069638

5/2019

0378-1722-93

Amlodipine and Valsartan Tablets, USP 10/160 mg

Bottles of 30

3069639

6/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3064086

1/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3066061

3/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3066062

3/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3073145

9/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3073146

9/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3073147

9/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3076091

11/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3077619

11/2019

0378-1723-93

Amlodipine and Valsartan Tablets, USP 5/320 mg

Bottles of 30

3082432

3/2020

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3066064

3/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3069645

6/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3069646

6/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3073142

9/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3073143

9/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3073144

9/2019

0378-1724-93

Amlodipine and Valsartan Tablets, USP 10/320 mg

Bottles of 30

3077617

11/2019






NDC

Name and Strength

Size

Lot No

Expiry

0378-5807-93

Valsartan Tablets, USP 40 mg

Bottles of 30

3063780

1/2019

0378-5807-93

Valsartan Tablets, USP 40 mg

Bottles of 30

3074879

10/2019

0378-5807-93

Valsartan Tablets, USP 40 mg

Bottles of 30

3086684

6/2020

0378-5807-93

Valsartan Tablets, USP 40 mg

Bottles of 30

3086687

6/2020

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3065445

2/2019

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3074880

10/2019

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3074883

10/2019

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3086688

6/2020

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3086689

6/2020

0378-5813-77

Valsartan Tablets, USP 80 mg

Bottles of 90

3086710

6/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3069019

5/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3069020

5/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3069021

5/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3069022

5/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3071354

7/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3071355

7/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3071357

7/2019

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079023

1/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079027

1/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079028

1/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079029

1/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079996

2/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079997

2/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3079998

2/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3083635

4/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3086715

6/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3086716

7/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3086717

7/2020

0378-5814-77

Valsartan Tablets, USP 160 mg

Bottles of 90

3088623

8/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3063783

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3063784

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3063785

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3064092

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3064093

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3064094

1/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070349

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070350

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070351

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070352

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070353

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3070354

6/2019

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3079030

1/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3079031

1/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3079032

1/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3079033

1/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3080011

2/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3080224

2/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3081498

3/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3081500

3/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3087126

7/2020

0378-5815-77

Valsartan Tablets, USP 320 mg

Bottles of 90

3088476

8/2020






NDC

Name and Strength

Size

Lot No

Expiry

0378-6321-77

Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

Bottles of 90

3084363

2/2019

0378-6321-77

Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

Bottles of 90

3084364

2/2019

0378-6321-77

Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

Bottles of 90

3093800

12/2019

0378-6321-05

Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

Bottles of 500

3084363

2/2019

0378-6321-05

Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

Bottles of 500

3093800

12/2019

0378-6322-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 90

2008880

8/2020

0378-6322-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 90

3084358

2/2019

0378-6322-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 90

3084359

2/2019

0378-6322-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 90

3093801

12/2019

0378-6322-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 500

3084359

2/2019

0378-6322-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 500

3084361

2/2019

0378-6322-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

Bottles of 500

3093801

12/2019

0378-6323-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

Bottles of 90

3084887

2/2019

0378-6323-77

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

Bottles of 90

3093802

12/2019

0378-6323-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

Bottles of 500

3084887

2/2019

0378-6323-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

Bottles of 500

3084888

2/2019

0378-6323-05

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

Bottles of 500

3093802

12/2019

0378-6324-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

Bottles of 90

3084889

2/2019

0378-6324-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

Bottles of 90

3093803

12/2019

0378-6324-05

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

Bottles of 500

3084890

2/2019

0378-6324-05

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

Bottles of 500

3093803

12/2019

0378-6325-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 90

3084860

2/2019

0378-6325-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 90

3084861

2/2019

0378-6325-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 90

3084862

2/2019

0378-6325-77

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 90

3093804

12/2019

0378-6325-05

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 500

3084862

2/2019

0378-6325-05

Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

Bottles of 500

3084863

2/2019

Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction. Valsartan in combination with amlodipine or hydrochlorothiazide is used for the treatment of high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products. Wholesalers, retailers and consumers that are in possession of recalled product should contact Stericycle at 1-888-406-9305 for the return of the recalled product. Normal business hours are Monday through Friday 8 a.m. to 5 p.m. EST.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

  • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

Product Photos

SOURCE Mylan N.V.

Related Links

http://www.mylan.com

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.